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BRIEF DEFINITIVE REPORT
Invariant natural killer T (iNKT) cells consti-
tute a peculiar T lymphocyte subset, which is 
characterized by the coexpression of NK mark-
ers and an invariant TCR- chain (V14J18 
in mouse or V24J18 in human), which pairs 
with a restricted number of TCR- chains (V8, 
V7, and V2 in mice and V11 in human). 
iNKT cells recognize glycolipid antigens, such 
as -galactosylceramide (-GalCer), presented 
in the context of CD1d molecules (1). iNKT 
cells develop in the thymus from CD4+ CD8+ 
double-positive (DP) cells that have randomly 
rearranged the semiinvariant TCR and are 
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The Wiskott-Aldrich syndrome (WAS) protein (WASp) is a regulator of actin cytoskeleton 
in hematopoietic cells. Mutations of the WASp gene cause WAS. Although WASp is in-
volved in various immune cell functions, its role in invariant natural killer T (iNKT) cells has 
never been investigated. Defects of iNKT cells could indeed contribute to several WAS 
features, such as recurrent infections and high tumor incidence. We found a profound 
reduction of circulating iNKT cells in WAS patients, directly correlating with the severity of 
clinical phenotype. To better characterize iNKT cell defect in the absence of WASp, we 
analyzed was/ mice. iNKT cell numbers were significantly reduced in the thymus and 
periphery of was/ mice as compared with wild-type controls. Moreover analysis of was/ 
iNKT cell maturation revealed a complete arrest at the CD44+ NK1.1 intermediate stage. 
Notably, generation of BM chimeras demonstrated a was/ iNKT cell-autonomous devel-
opmental defect. was/ iNKT cells were also functionally impaired, as suggested by the 
reduced secretion of interleukin 4 and interferon  upon in vivo activation. Altogether, 
these results demonstrate the relevance of WASp in integrating signals critical for develop-
ment and functional differentiation of iNKT cells and suggest that defects in these cells 
may play a role in WAS pathology.
© 2009 Locci et al. This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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Thus far, many cellular defects resulting from the absence 
of WASp have been described, revealing the involvement of 
this protein in regulation of migration, cell trafficking and 
immunological synapse (IS) formation in distinct immune cell 
types (9). Aside from its role in actin cytoskeleton remodeling, 
WASp is required in signaling pathways downstream from 
NK and T cell activation (10–12). Although impaired innate 
and adaptive immune cell function can account for infections 
and partially explain the increased susceptibility to developing 
cancer and autoimmunity, a full comprehension of the cellular 
mechanisms underlying the pathogenesis of this syndrome still 
needs to be achieved (9, 13).
In the present work, we provide evidence that iNKT cells 
are absent in full-blown WAS patients. Moreover, analysis of 
iNKT cells in was/ mice revealed defects in iNKT cell mat-
uration and function. Our data point to a new role for WASp 
as an important regulator of iNKT cell development and 
function and lead to the hypothesis that these defects could 
contribute to the immune dysregulation in WAS.
RESULTS AND DISCUSSION
WAS patients, but not XLT patients, lack circulating iNKT cells
To investigate whether WASp deficiency has an impact on the 
amount of circulating human iNKT cells, we examined pe-
ripheral blood from three patients with a mild clinical pheno-
type (score of 1–2, XLT), six patients with severe WAS (score 
3–5), and 13 age-matched healthy donors (HDs; Table S1). By 
flow cytometry, iNKT cells were nearly undetectable in WAS 
patients with a severe score (Fig. 1 A). Interestingly, three pa-
tients with XLT presented a detectable number of iNKT cells, 
even though their median value was within the lower range 
of HDs (Fig. 1 B). Therefore, impairment in iNKT cell num-
ber correlates with the severity of disease. In severe WAS pa-
tients lacking iNKT cells, the frequency of T cells expressing 
either TCR V24 or V11, although variable, was in the 
range of HDs, suggesting that these TCR V regions can be 
used by WASp-deficient T cells (Fig. S1). Moreover, the 
analysis of the TCR V repertoire in three WAS patients 
(WAS1, WAS28, and WAS33) and one case of  XLT (WAS30) 
revealed the presence of all TCR V families, with some 
positively selected by recognition of CD1d molecules on DP 
thymocytes. After positive selection, the most immature iNKT 
cells (stage 1, CD44 NK1.1) first differentiate into CD44+ 
NK1.1 (stage 2) and then are either exported into the pe-
riphery or remain in the thymus. In both compartments, iNKT 
cells complete their maturation, becoming CD44+ NK1.1+ 
mature cells (stage 3) (2). This differentiation program re-
quires signaling molecules, adapters, and transcription factors 
that selectively control the development of iNKT and not of 
mainstream T cells (2).
Mature iNKT cells are strong immunoregulatory ele-
ments because they promptly produce a wide range of cyto-
kines upon TCR triggering (1). iNKT cells are indeed 
involved in the control of pathogen infection and cancer 
immunosurveillance (3, 4) and play a protective role in many 
autoimmune diseases, although in some autoimmune mouse 
models they can exert a detrimental activity (5).
Interestingly, a complete lack of iNKT cells was found in 
the X-linked lymphoproliferative disease (XLP) (6), a primary 
immunodeficiency which is caused by mutations in SAP and 
XIAP genes and characterized by inappropriate response to 
EBV infection, usually leading to B cell lymphoma. The ab-
sence of iNKT cells reveals a role for SAP and XIAP in the reg-
ulation of iNKT cell development and implies the contribution 
of this cell subset to the control of infections and cancer pro-
gression. In keeping with the iNKT cell immunoregulatory 
role, their absence has been recently described in the Omenn 
syndrome, a primary immunodeficiency characterized by se-
vere autoimmune manifestations (7). All these evidences have 
prompted us to investigate iNKT cells in Wiskott-Aldrich syn-
drome (WAS), a primary immunodeficiency associated with 
thrombocytopenia, recurrent infections, increased risk of devel-
oping cancer (mainly B cell lymphoma EBV associated), and 
autoimmunity (8, 9). WAS is caused by mutations in the gene 
encoding for the WAS protein (WASp), a key regulator of ac-
tin-dependent processes in hematopoietic cells (9). In humans, 
complete lack of WASp gives rise to the severe WAS pheno-
type, whereas hypomorphic mutations allowing residual WASp 
expression usually lead to X-linked thrombocytopenia (XLT), 
a milder disease characterized by marginal immune defects (8).
Figure 1. Lack of iNKT cells in WAS patients. (A) Representative flow cytometric analysis of peripheral blood iNKT cells from an age-matched HD control (HD), 
an XLT patient (XLT), and a WAS patient (WAS). Cells in the density plots are gated on CD3+ cells. Percentages of iNKT cells (TCR-V11+ TCR-V24+) are indicated.  
(B) Frequency of iNKT cells from 13 controls, 3 XLT, and 6 WAS patients. Bars represent the median value of each group. ns, P > 0.05; *, P < 0.05; ***, P < 0.001.
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stained specifically with -GalCer–loaded CD1d tetramers 
was not significantly decreased in was/ thymi, whereas it was 
two- and threefold reduced in spleen and liver, respectively, of 
was/ animals compared with WT controls (Fig. 2 A and not 
depicted). However, the absolute number of iNKT cells was 
significantly reduced in all three compartments of was/ 
mice in comparison with WT mice (Fig. 2 B).
Based on CD4 expression, two iNKT cell subsets can be dis-
tinguished: CD4+ and CD4 CD8 double-negative (DN) cells 
(1). We analyzed whether the lack of WASp could affect the de-
velopment and/or tissue distribution of one particular iNKT cell 
subset. Comparison of the absolute number of iNKT cells in 
was/ and WT animals revealed a significant reduction of both 
CD4+ and DN iNKT cells in was/ mice in all tissues, with the 
exception of DN cells in the spleen. However no skewing to-
ward one particular subset was observed (Fig. 2 C).
These findings indicate that the lack of WASp causes a 
significant decrease of iNKT cell number. We thus investi-
gated whether the reduction of iNKT cells in was/ mice 
might be the result of an altered thymic development. We 
first analyzed the expression of CD1d, which is required for 
iNKT cell positive selection (17), on DP lymphocytes with-
out finding any alteration in was/ mice in comparison with 
WT mice (Fig. S2).
alterations probably caused by infections, which are frequent 
in these patients (Table S2). These findings indicate a pro-
found defect in iNKT cell population, despite minor altera-
tions in the TCR repertoire of mainstream T cells.
iNKT cell absence could contribute to the increased sus-
ceptibility of patients to pathogen infections. Indeed, lack of 
iNKT cells can impair the immune protection against viral, 
bacterial, and fungal infections (3). Furthermore, iNKT cells 
play a key role in tumor immunosurveillance, as suggested by 
the increased susceptibility of NKT-deficient mice to develop-
ing cancer (4) and a decreased iNKT cell number in patients 
with advanced cancer (14, 15). Therefore, we hypothesize that 
the absence of iNKT cells might contribute to the high suscep-
tibility to develop EBV+ B cell lymphoma observed in WAS 
patients, as has also been suggested for XLP (6).
Impaired iNKT cell development in was/ mice
Given the paucity of material derived from WAS patients, we 
further investigated the role of WASp in the development 
and function of iNKT cells in was/ mice (16). This mouse 
model recapitulates important immune system alterations of 
the human WAS (16). We first investigated the number and 
distribution of iNKT cells in the thymus, liver, and spleen by 
flow cytometric analysis. The percentage of iNKT cells 
Figure 2. Reduced iNKT cell number in was/ mice. (A) iNKT cells were analyzed by flow cytometry in thymus, liver, and spleen of C57BL/6 WT and 
was/ mice (was/). Thymocytes were stained with anti-CD8, anti-CD3 mAbs, and CD1d tetramers (-GalCer loaded or unloaded), whereas hepatic leuko-
cytes and splenocytes were stained with anti-B220 and anti-CD3 mAbs and CD1d tetramers (-GalCer loaded or unloaded). After gating on CD8 or B220 
cells, iNKT cells were identified as CD3+ CD1d tetramers+ cells. (B) Absolute numbers of iNKT cells were determined by multiplying their percentage by the 
absolute cell count within each sample. In A and B, data are representative of at least 10 mice per group analyzed in three independent experiments. (C) iNKT 
cells were stained with anti-CD4 antibodies. Comparison of the absolute number of CD4+ or CD4 (DN) iNKT cells in thymus, liver, and spleen in WT versus 
was/ mice is shown. In B and C, error bars represent the median and interquartile ranges of eight mice per group. *, P < 0.05; **, P < 0.005; ***, P < 0.001.
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BM chimeras by reconstituting irradiated CD45.1 mice with a 
mixture of equal numbers of CD45.2 lineage-negative (lin) cells 
from the BM of was/ and WT mice. This way, CD45.2 was/ 
iNKT cell precursors would develop in the presence of donor-
derived CD45.2 DP thymocytes and hematopoietic cells from 
either was/ or WT mice. In case of an iNKT cell-intrinsic de-
fect, the presence of WT cells would not be sufficient to rescue 
the development of was/ iNKT cells. BM chimeras were an-
alyzed 7–9 wk after transplantation and evaluated for the expan-
sion and maturation of iNKT cells derived from either was/ 
or WT hematopoietic precursors. As shown in Fig. 4 A, the 
percentage of iNKT cells developing in was/ mice reconsti-
tuted with was/ lin cells (WAS/→WAS/ control) was 
reduced both in the thymus and, more markedly, in the periph-
ery when compared with that observed in WT recipients trans-
planted with WT precursors (WT→WT control). Both mixed 
BM chimeras generated in was/ and WT recipients displayed 
a level of iNKT cells similar to the WT→WT control, suggest-
ing the same capacity of WT and was/ recipients to support 
iNKT cell generation. The analysis of maturation of donor 
iNKT cells based on NK1.1 expression confirmed the com-
plete developmental block of was/ iNKT cells in WAS/→
WAS/ controls as opposed to successful maturation of 
WASp+ iNKT cells in the WT→WT control (Fig. 4 B). In the 
We next investigated the maturation steps of iNKT cells 
after positive selection, using CD44 and NK1.1 markers. As 
shown in Fig. 3 A, was/ iNKT cells were mainly arrested at 
CD44+ NK1.1 stage, and only a minor fraction became 
NK1.1+ both in the thymus and in periphery. The analysis of 
the absolute number of iNKT cells during the different matu-
ration steps confirmed that WASp does not affect the earliest 
developmental phase, when was/ iNKT cells are normally 
present (Fig. 3 B). Conversely was/ iNKT cells accumulate 
at stage 2 (CD44+ NK1.1) without progressing to stage 3 
(CD44+NK1.1+), suggesting a potential role of WASp in reg-
ulating the late phases of the differentiation process.
Among the events contributing to the final maturation 
of iNKT cells in the periphery, a crucial role seems to be 
played by CD1d recognition because NK1.1 iNKT cells 
fail to properly complete their maturation in the absence of 
CD1d (18). To address this point, we examined CD1d ex-
pression in the periphery of was/ mice, finding expression 
levels comparable to those of the WT (Fig. S2). These data 
rule out the possibility that an altered CD1d expression in 
the periphery may have a role in developmental block of 
was/ iNKT cells.
Next, to assess whether the developmental defect of iNKT 
cells in was/ mice is cell autonomous, we generated mixed 
Figure 3. Block iNKT cell maturation in the absence of WASp. (A) Thymocytes and hepatic leukocytes from WT and was/ mice were stained with 
anti-CD8, anti-CD3, anti-CD44, and anti-NK1.1 mAbs and -GalCer–loaded CD1d tetramers. Maturation of iNKT cells (CD1d tetramer+, CD3+, and CD8) 
was assessed by CD44 and NK1.1 expression. Data are representative of six mice per group analyzed in two independent experiments. (B) Absolute num-
bers of iNKT cells (CD1d tetramer+, CD3+, and CD8) in thymus and liver of WT and was/ mice. Error bars represent median and interquartile range of 
six mice per group. **, P < 0.005.
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Many players regulating iNKT cell terminal maturation are 
molecules involved in the TCR signaling. For instance, a lower 
iNKT generation and maturation was observed in the absence 
of PKC-, a signal transduction molecule which is known to 
play an important role in the TCR–NF-B pathway (19). It is 
of note that PKC-–mediated phosphorylation can activate 
WASp at the IS (20). Thus, in iNKT cell development, WASp 
BM chimeras, although WASp+ iNKT cells could acquire the 
mature phenotype in both recipients, WASp iNKT cells were 
unable to up-regulate NK1.1, even in the presence of hemato-
poietic cells derived from WT progenitors. Altogether, these 
findings demonstrate that the lack of WASp determines an 
iNKT cell–autonomous defect that impairs the maturation, sur-
vival, and/or expansion of these cells.
Figure 4. Cell-autonomous developmental defect of was/ iNKT cells. (A) iNKT cells were analyzed by flow cytometry in thymus and liver of WT 
or was/ recipient mice (CD45.1) transplanted with was/ lin cells, WT lin cells, or a mixture of 50% WT and 50% was/ lin obtained from CD45.2 
mice. Thymocytes and hepatic leukocytes were surface stained with -GalCer–loaded CD1d tetramers, with anti-CD3 and anti-CD8 (thymocytes) or anti-
B220 (hepatic leukocytes) mAbs. The percentage of iNKT cells (CD8 or B220 CD3+CD1d tetramer+ cells) is indicated in each plot. (B) Maturation of iNKT 
cells in thymus and liver of BM chimera mice. After gating on donor CD45.2+, iNKT cells were further analyzed for NK1.1 and WASp expression. The per-
centage of mature (NK1.1+) and immature (NK1.1) iNKT cells from WT donors (WASp+) or from was/ donors (WASp) is indicated in each plot. Data 
are representative of at least three mice per group from two independent experiments.
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support the hypothesis that WASp acts as an important com-
ponent in the downstream events of TCR pathway during 
iNKT cell terminal maturation.
Impaired function of was/ iNKT cells
To investigate whether iNKT cells also exhibit functional 
defects in the absence of WASp, we evaluated the in vivo re-
sponse to -GalCer, a synthetic glycosphingolipid that elicits 
a prompt and selective activation of iNKT cells through the 
CD1d molecule. Upon -GalCer stimulation, iNKT cells 
quickly produce huge amounts of Th1 and Th2 cytokines. 
We injected 1 µg -GalCer i.v. into was/ mice and WT 
controls and evaluated IL-4 and IFN- production in the sera 
of treated animals 3, 6, 12, and 24 h after stimulation. Al-
though in was/ mice the kinetics of cytokine production 
was similar to that in WT mice, the amount of IL-4 and IFN-
 in was/ sera was significantly reduced at every time point 
that was tested (Fig. 5 A). The lower cytokine levels could be 
a result of the reduced iNKT cell number in was/ mice but 
also of the impaired ability of was/ iNKT cells to produce 
cytokines. To address this issue, we administered -GalCer 
to was/ or WT mice and analyzed ex vivo the intracellular 
cytokine production by iNKT cells. 45 min after -GalCer 
injection, a significant fraction of WT iNKT cells produced 
a considerable amount of intracellular IL-4 and IFN-, 
might be a relevant target of the activated PKC- in the 
TCR–NF-B pathway. In addition, iNKT cell development 
requires TCR-induced transcriptional factors, such as NF-
B, AP-1, and T-bet (2), whose expression or function are 
altered in the absence of WASp (10–12). Indeed, a reduced 
iNKT cell generation and maturation was associated with the 
absence of the transcriptional factor NF-B (21), and WASp 
was demonstrated, at least in NK cells, to be involved in the 
regulation of NF-B nuclear translocation (10). Moreover, 
transgenic mice overexpressing BATF, a negative regulator 
of AP-1 activity, showed defective maturation of iNKT cells 
(22, 23). Interestingly, WASp absence was associated with a 
lower AP-1 binding activity in mouse T cells (12). A severe 
block in NK1.1 expression was also reported in mice lacking 
T-bet, a transcriptional factor associated to Th1 immunity 
(24). A possible role for WASp in the regulation of T-bet is 
supported by a recent study from our group showing a re-
duced T-bet expression in TCR-stimulated CD4+ T cell 
lines from WAS patients (11). Furthermore, very recent evi-
dences have highlighted the critical role of costimulatory sig-
nals arising from B7–CD28 interaction in promoting the 
expansion of mature NK1.1+ iNKT cells (25, 26). Interest-
ingly, WASp was demonstrated to be required for a normal 
ligation-induced CD28 endocytosis, a process which is rele-
vant to CD28 costimulatory functions (27). These evidences 
Figure 5. Impaired cytokine production by was/ iNKT cells. (A) In vivo IL-4 and IFN- production upon -GalCer administration in WT and was/ 
mice. Sera were analyzed at 3, 6, 12, and 24 h upon injection. The graphs show the amount of cytokines produced by six WT and six was/ mice. Black and 
white squares represent the median values of WT and was/ mice groups, respectively. The vertical bars represent the interquartile range of each group. *, 
P < 0.05; **, P < 0.005. (B) IL-4 and IFN- production in WT and was/ mice at the single iNKT cell level. WT and was/ mice were injected with -GalCer 
and, after 45 min, hepatic leukocytes were isolated and stained with -GalCer–loaded CD1d tetramers and anti-CD3, anti–IL-4, and anti–IFN- mAbs. Rep-
resentative analysis of IL-4 and IFN- intracellular production by iNKT cells (CD3+ and CD1d tetramer+) from WT (thick line) and was/ (thin line) mice is 
shown. Filled histograms represent IL-4 or IFN- production by untreated WT mice. Data are from one representative experiment of three.
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expressing cells. The stable IS may allow developing iNKT 
cells to receive and integrate various agonist signals, originating 
from invariant TCR engagement and costimulatory molecules, 
to achieve full differentiation. Indeed, the defective was/ 
iNKT cells resemble the ones generated in the absence of 
signal transduction molecules or transcription factors, such as 
PKC-, NF-B, or T-bet. These molecules belong to the 
complex cascade of events generated upon TCR triggering and 
IS formation in conventional T cells and regulate iNKT cell 
expansion or survival, maturation, and cytokine production 
(19, 21, 24). Furthermore, the genetic deletion of costimula-
tory molecules, such as CD28, affects expansion and pheno-
typic and functional differentiation of iNKT cells (25, 26).
In conclusion, these findings provide the first evidence that 
WASp acts as an important player for the generation of mature 
and functional iNKT cells. Moreover, our data add a new per-
spective in the comprehension of the complex immune dys-
regulation and tumor susceptibility characterizing WAS.
MATERIALS AND METHODS
Patients. Blood samples from patients and age-matched HDs were obtained 
according to standard ethical procedures and with the approval of the San 
Raffaele Scientific Institute Internal Review Board (TIGET02).
Mice. C57BL/6 (B6) was/ mice were provided by K.A. Siminovitch (Samuel 
Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Canada) (16). 
CD45.1 was/ mice were generated in our facility. B6 WT mice were pur-
chased from Charles River Laboratories. All mice were 8–12 wk old. Experi-
ments were performed according to protocols approved by the Animal Care and 
Use Committee of the San Raffaele Scientific Institute (IACUC318).
Cell preparation and flow cytometry. Human PBMCs were purified on 
Ficoll gradient (PoC; Axis-Shield) and stained with anti-CD4 (RPAT4; BD), 
anti-CD3 (UCHT1; BD), anti–TCR-V24 (C15; Beckman Coulter), and 
anti–TCR-V11 (C21; Beckman Coulter) antibodies. For mouse studies, sin-
gle cell suspensions were obtained from liver, spleen, and thymus. Hepatic leu-
kocytes were purified using a Percoll (Sigma-Aldrich) gradient. The following 
mAbs were used for surface staining: anti-B220 (RA3-6B2), anti-CD8a (53–
6.7), anti-CD4 (RM4-5), anti-CD44 (IM7), and anti-CD45.2 (104; all pur-
chased from BD); anti-CD3 (17A2) and anti-NK1.1 (PK136; both purchased 
from BioLegend); and CD1d tetramers (ProImmune). For lipid loading, CD1d 
tetramers were incubated overnight with a 12 molar excess of -GalCer (Axx-
ora). Intracytoplasmic staining was performed using the Cytofix/Cytoperm kit 
(BD) and the following mAbs: anti–IFN- (XMG1.2) and anti–IL-4 (11B11; 
BD). Anti-WASp antibody was provided by H. Ochs (Research Center for 
Immunity and Immunotherapies, Seattle Children’s Research Institute, Uni-
versity of Washington, Seattle, WA). Cells were acquired on a FACS CANTO 
(BD) and analyzed with FlowJo Software (Tree Star, Inc.).
Generation of BM chimeras. BM lin cells from CD45.2 B6 WT or 
was/ mice were purified with the mouse hematopoietic progenitor en-
richment kit (StemCell Technologies Inc.). Was/ recipient mice (CD45.1) 
were irradiated (900 rad) before receiving i.v. 2.5 × 105 lin cells. Reconsti-
tution was monitored by flow cytometry on blood cells. Mice were sacri-
ficed 7–9 wk after transplantation for the analysis of iNKT cells in thymus 
and liver. Thymocytes were depleted of CD8+ cells by magnetic beads 
(Miltenyi Biotec) to enrich iNKT cell fraction.
In vivo activation and cytokine production. WT and was/ mice 
were i.v injected with 1 µg -GalCer in PBS or not injected as controls. To 
measure the in vivo IL-4 and IFN- production, blood samples were col-
lected 3, 6, 12, and 24 h after injection. Serum cytokine levels were mea-
sured by Bio-Plex Technology (Bio-Rad Laboratories). To test the ex vivo 
whereas was/ iNKT cells showed an impaired production 
of both cytokines (Fig. 5 B). In parallel, we evaluated the in 
vivo iNKT cell expansion induced by -GalCer injection. 
The analysis of iNKT cell number at different time points (3, 
7, and 11 d) revealed, as expected, a peak of expansion of WT 
iNKT cell at day 3 followed by a contraction at day 7. Con-
versely, was/ iNKT cells showed a delayed kinetics with 
maximum expansion at day 7 followed by a contraction at day 
11 (Fig. S3 A). The increase of was/ iNKT cell absolute 
number induced by -GalCer was significant compared with 
the untreated mice. However, the capacity of was/ iNKT 
cells to expand was substantially lower than WT iNKT cells, as 
shown by the differences in fold increase values (Fig. S3 B).
The functional defect of was/ iNKT cells was further con-
firmed by their inability to help antigen-specific B cell responses 
in vivo compared with WT-activated iNKT cells (28). The 
functional impairment of was/ iNKT cells upon in vivo acti-
vation may not be caused by their arrest at the immature stage 
2 of differentiation because peripheral WT iNKT with imma-
ture phenotype are able to produce both Th1 and Th2 cytokines 
(29). On the contrary, it may result from various factors such as 
alterations in antigen presentation, an improper interaction be-
tween iNKT cells and APC, or a cell-autonomous defect.
Indeed, the activation of iNKT cells requires TCR recogni-
tion of a glycolipid antigens–CD1d complex on the surface of 
APCs (1). It is possible that a reduced antigen presentation ability 
of was/ APC may contribute to the in vivo impaired function-
ality of was/ iNKT cells because was/ DC have a reduced 
ability to migrate, assemble podosomes, and process particulate 
antigens (9). Moreover, it is tempting to speculate that iNKT 
cells, like conventional T lymphocytes, require IS formation to 
achieve a proper activation. In the absence of WASp, this process 
has been demonstrated to be defective (30). Furthermore, altered 
activation of transcriptional factors NF-AT and AP-1, occurring 
in the absence of WASp (11, 12), may affect not only the devel-
opment, as discussed in previous paragraphs, but also iNKT cell 
function. In particular, reduction in NF-AT activation and alter-
ation in nuclear translocation correlates with the impaired IL-2 
production observed in was/ T lymphocytes (11, 12). In agree-
ment with this hypothesis, mouse models carrying defects in 
molecules involved in the activation of AP-1 present alteration 
in iNKT cells including a perturbed cytokine profile (22).
Altogether, these results show that the lack of WASp leads 
to profound alterations in iNKT cells, which are absent in se-
vere WAS patients and reduced in the was/ mouse model. In 
was/ mice, accumulation of immature iNKT cells (CD44+ 
NK1.1), together with the lack of mature subset, suggests a 
key role for WASp in iNKT cell maturation process. More-
over, analysis of in vivo stimulation and cytokine production 
reveals that peripheral iNKT cells are functionally impaired in 
was/ mice. WASp is known as a central player in T cell acti-
vation by controlling actin polymerization, which in turn fa-
vors the generation of a long-lived IS between T cells and 
APCs (30, 31). We hypothesize that the postselection expan-
sion and differentiation of iNKT cells requires the formation of 
a proper IS between developing iNKT cells and CD1d- 
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IL-4 and IFN- intracellular production by liver iNKT cells, mice were sac-
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Statistical analysis. All data were analyzed with a two-tailed Mann- 
Whitney U test.
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clinical status of patients. Table S2 shows the TCR-V repertoire of HD and 
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single-positive cells in HD, XLT, and WAS patients. Fig. S2 depicts CD1d 
expression in DP thymocytes and in splenic B cells and DCs. Fig. S3 shows 
iNKT cell in vivo expansion upon -GalCer injection. Fig. S4 describes iNKT 
cell help to antigen-specific antibody responses. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20081773/DC1.
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